This is a molecule that is directly linked to the expression of the cellular prion protein found on the surface of nerve cells. The study, led by the IBEC, opens the door to the early detection of Alzheimer’s disease in asymptomatic stages in blood samples, favouring its diagnosis and treatment.
A recent study led by the Molecular and Cellular Neurobiotechnology group at the IBEC and the University of Barcelona has identified a new biomarker for Alzheimer’s disease in asymptomatic stages of the disease. The molecule is miR-519a-3p, a microRNA directly linked to the expression of the cellular prion protein (PrPC), which is deregulated in people suffering from some neurodegenerative diseases such as Alzheimer’s.
The search for biomarkers that are stable and easily detectable in biofluids, such as microRNAs, offers hope for detecting Alzheimer’s disease in its early, asymptomatic stages. Early detection could significantly improve the diagnosis and treatment of this disease, which affects more than 35 million people worldwide.
First link between miR-519a-3p and PrPC in Alzheimer’s disease
The expression of some microRNAs is known to be deregulated in Alzheimer’s patients. However, this is the first time that this microRNA has been specifically linked to the decrease in cellular prion protein production during disease progression.
“Currently, tests to diagnose Alzheimer’s disease are usually carried out after the onset of symptoms, when there is already underlying cognitive impairment. We believe that the detection of this microRNA may help to establish additional criteria for a more accurate diagnosis in the early stages of the disease,” explains IBEC principal investigator José Antonio del Río, full professor at the Faculty of Biology and the Institute of Neurosciences of the University of Barcelona (UB) and co-leader of the study.
We believe that the detection of this microRNA may help to establish additional criteria for a more accurate diagnosis in the early stages of the disease
José Antonio del Río
The study also comparatively analyses the presence of the biomarker in samples from other neurodegenerative diseases:
“If our goal is to use miR-519a-3p as a biomarker to detect Alzheimer’s dementia in hypothetically healthy people, it is essential to ensure that its levels are not altered in other neurodegenerative diseases. In our study, we compared the levels of this biomarker in samples from other tauopathies and Parkinson’s disease, confirming that the changes in miR-519a-3p are specific to Alzheimer’s disease,” said IBEC senior researcher Rosalina Gavín, UB associate professor and co-leader of the study.
Dayaneth Jácome, a researcher in del Río’s group and first author of the study, says that the team is making progress: “The next step is to validate miR-519a-3p as a biomarker in blood samples from different cohorts of patients, in order to start using it in the clinical diagnosis of Alzheimer’s disease in peripheral samples.”
The next step is to validate miR-519a-3p as a biomarker in blood samples from different cohorts of patients.
Dayaneth Jácome
The researchers are members of the Center for Networked Biomedical Research in Neurodegenerative Diseases, CIBERNED.
MicroRNAs: gene silencers
The amount of cellular prion protein changes over the course of Alzheimer’s disease, with higher levels in the early stages of the disease and lower levels as the disease progresses. Although the mechanism responsible for these changes is not known in detail, it has been observed that certain microRNAs bind to a specific region of the PRNP gene that controls PrPC expression, reducing it. For this reason, and based on comparisons of previous studies and computational analyses in various genomic databases, the researchers selected the microRNA miR-519a-3p for their study.
Referenced paper:
Dayaneth Jácome, Tiziana Cotrufo, Pol Andrés-Benito, Laia Lidón, Eulàlia Martí, Isidre Ferrer, José Antonio del Río, Rosalina Gavín. miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages. BBA – Molecular Basis of Disease (2024). DOI: https://doi.org/10.1016/j.bbadis.2024.167187
